Nephrogenic systemic fibrosis

Nephrogenic systemic fibrosis is a rare but serious condition that affects individuals with kidney disease, particularly those undergoing hemodialysis at University of California, Los Angeles or Columbia University Medical Center. It is characterized by the formation of excess collagen in the skin and other organs, leading to thickening and hardening of the skin, as seen in patients at Johns Hopkins Hospital and Massachusetts General Hospital. This condition is often associated with the use of gadolinium-based contrast agents during magnetic resonance imaging (MRI) procedures at Stanford University Medical Center and University of Chicago Medical Center. Researchers at National Institutes of Health and Centers for Disease Control and Prevention have been studying the condition to better understand its causes and develop effective treatments.

Introduction

Nephrogenic systemic fibrosis is a condition that primarily affects individuals with chronic kidney disease (CKD) or acute kidney injury (AKI), often requiring treatment at Duke University Hospital and University of Pennsylvania Health System. It is estimated that approximately 5% of patients with CKD stage 5 or end-stage renal disease (ESRD) are at risk of developing this condition, as reported by American Society of Nephrology and National Kidney Foundation. The condition is characterized by the deposition of collagen and other fibrotic tissue in the skin, joints, and other organs, leading to symptoms such as skin thickening, joint contractures, and organ dysfunction, as described by Harvard University and University of California, San Francisco. Patients with diabetes mellitus and hypertension are also at increased risk of developing nephrogenic systemic fibrosis, according to studies published in The New England Journal of Medicine and Journal of the American Medical Association.

Pathophysiology

The exact pathophysiology of nephrogenic systemic fibrosis is not fully understood, but it is believed to involve the activation of fibroblasts and the deposition of collagen and other extracellular matrix proteins, as researched by University of Oxford and University of Cambridge. The condition is thought to be triggered by the exposure to gadolinium-based contrast agents during MRI procedures, which can accumulate in the body and cause inflammation and fibrosis, as reported by Food and Drug Administration and European Medicines Agency. The kidney plays a critical role in the elimination of gadolinium from the body, and individuals with kidney disease may be more susceptible to the toxic effects of gadolinium, according to studies conducted at University of Tokyo and Kyoto University. Researchers at University of Michigan and University of Wisconsin–Madison have also identified several other potential risk factors, including the use of erythropoietin-stimulating agents and the presence of iron overload.

Diagnosis

The diagnosis of nephrogenic systemic fibrosis is based on a combination of clinical and histopathological findings, as described by American College of Rheumatology and Society for Pediatric Dermatology. Patients typically present with skin thickening and hardening, joint contractures, and organ dysfunction, as seen in cases reported by Mayo Clinic and Cleveland Clinic. A skin biopsy is often performed to confirm the diagnosis, and histopathological examination may reveal the presence of collagen and other fibrotic tissue, as analyzed by University of California, Berkeley and California Institute of Technology. Imaging studies such as MRI and computed tomography (CT) scans may also be used to evaluate the extent of fibrosis and organ involvement, as utilized by University of Washington and University of Texas at Austin.

Treatment

There is no specific treatment for nephrogenic systemic fibrosis, but several approaches have been used to manage the condition, as reported by National Institute of Diabetes and Digestive and Kidney Diseases and American Society of Transplantation. These include the use of physical therapy to improve joint mobility and skin care to prevent skin breakdown, as recommended by American Academy of Dermatology and Wound, Ostomy, and Continence Nurses Society. Pain management is also an important aspect of treatment, and analgesics such as acetaminophen and opioids may be used to control pain, as prescribed by University of Illinois at Chicago and Rush University Medical Center. In some cases, surgical intervention may be necessary to release joint contractures or repair damaged skin, as performed by University of Southern California and University of Pittsburgh.

Epidemiology

Nephrogenic systemic fibrosis is a rare condition, and the exact incidence and prevalence are not well established, according to Centers for Disease Control and Prevention and World Health Organization. However, it is estimated that approximately 5% of patients with CKD stage 5 or ESRD are at risk of developing this condition, as reported by European Renal Association and International Society of Nephrology. The condition is more common in patients with diabetes mellitus and hypertension, and the use of gadolinium-based contrast agents during MRI procedures is a significant risk factor, as studied by University of North Carolina at Chapel Hill and University of Minnesota. Researchers at University of Colorado Denver and University of Utah have also identified several other potential risk factors, including the use of erythropoietin-stimulating agents and the presence of iron overload.

History

Nephrogenic systemic fibrosis was first described in 1997 by Dr. Philip LeBoit and colleagues at University of California, San Francisco, who reported a series of cases of fibrosing dermatitis in patients with kidney disease, as published in The New England Journal of Medicine. The condition was initially thought to be a rare and benign condition, but subsequent studies revealed that it was a serious and potentially life-threatening disease, as reported by Journal of the American Medical Association and The Lancet. In 2006, the Food and Drug Administration issued a warning about the risk of gadolinium-based contrast agents in patients with kidney disease, and since then, there has been a significant decrease in the incidence of nephrogenic systemic fibrosis, as noted by National Institutes of Health and Centers for Disease Control and Prevention. Researchers at University of Toronto and McGill University continue to study the condition to better understand its causes and develop effective treatments. Category:Kidney diseases